Abstract
AbstractLife expectancy has increased immensely over the past decades, bringing new challenges to the health systems as advanced age increases the predisposition for many diseases. One of those is the burden of neurologic disorders. While many hypotheses have been placed to explain aging mechanisms, it has been widely accepted that the increasing pro-inflammatory status with advanced age or “inflammaging” is a main determinant of biological aging. Furthermore, inflammaging is at the cornerstone of many age-related diseases and its involvement in neurologic disorders is an exciting hypothesis. Indeed, aging and neurologic disorders development in the elderly seem to share some basic pathways that fundamentally converge on inflammation. Peripheral inflammation significantly influences brain function and contributes to the development of neurological disorders, including Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis. Understanding the role of inflammation in the pathogenesis of progressive neurological diseases is of crucial importance for developing effective treatments and interventions that can slow down or prevent disease progression, therefore, decreasing its social and economic burden.
Funder
Fundação para a Ciência e a Tecnologia
Universidade do Porto
Publisher
Springer Science and Business Media LLC
Subject
Health, Toxicology and Mutagenesis,Toxicology,General Medicine
Reference226 articles.
1. Acosta-Rodriguez EV, Rivino L, Geginat J et al (2007) Surface phenotype and antigenic specificity of human interleukin 17–producing T helper memory cells. Nat Rev Immunol 8(6):639–646. https://doi.org/10.1038/s41577-020-0307-4
2. Adams NM, Grassmann S, Sun JC (2020) Clonal expansion of innate and adaptive lymphocytes. Nat Rev Immunol 20(11):694–707. https://doi.org/10.1038/s41577-020-0307-4
3. ADAPT Research Group, Lyketsos CG, Breitner JC, Green RC, Martin BK, Meinert C, Piantadosi S, Sabbagh M (2007) Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology 68(21):1800–1808. https://doi.org/10.1212/01.wnl.0000260269.93245.d2
4. Administration USFaD (2019) FDA approves new add-on drug to treat off episodes in adults with Parkinson’s disease. https://www.fda.gov/news-events/press-announcements/fda-approves-new-add-drug-treat-episodes-adults-parkinsons-diseases
5. Agrawal S, Baulch JE, Madan S et al (2022) Impact of IL-21-associated peripheral and brain crosstalk on the Alzheimer’s disease neuropathology. Cell Mol Life Sci 79(6):331. https://doi.org/10.1007/s00018-022-04347-6
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献